A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma

Astellas

Status and phase: Completed; Phase 2

Conditions: Melanoma

Treatments: Drug: YM155

Study type: Interventional

Funder types: Industry

Identifiers

NCT00281541

155-CL-008

Details and patient eligibility

About

A study with YM155 for the treatment of unresectable stage III or metastatic stage IV melanoma.

Full description

A phase II, multicenter, open-label study in subjects with unresectable Stage III or metastatic (Stage IV) Melanoma to evaluate the efficacy and safety of YM155

Enrollment: 29 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically or cytologically confirmed unresectable stage III or IV malignant melanoma
• Life expectancy >12 weeks

Exclusion criteria

• History of other malignancy in the last 5 years
• Major surgery within the past 21 days

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)